Study of the toxicity of a new lipid complex formulation of amphotericin B.

@article{Larabi2004StudyOT,
  title={Study of the toxicity of a new lipid complex formulation of amphotericin B.},
  author={M. Larabi and N. Pag{\`e}s and F. Pons and M. Appel and A. Gulik and J. Schlatter and S. Bouvet and G. Barratt},
  journal={The Journal of antimicrobial chemotherapy},
  year={2004},
  volume={53 1},
  pages={
          81-8
        }
}
OBJECTIVES The aim of this study was to evaluate the toxicity of a new lipid complex formulation of amphotericin B (LC-AmB) produced by a simple process. [...] Key Method Doses of LC-AmB up to 20 mg/kg were used, and compared with Fungizone at 0.5 mg/kg and Abelcet at 10 mg/kg. Acute toxicity after a single bolus injection was also determined, as well as the haemolytic activity and toxicity to mouse macrophages in vitro. Expand
Aerosolized liposomal amphotericin B: prediction of lung deposition, in vitro uptake and cytotoxicity.
TLDR
Results indicate that aerosol therapy with nebulized L-AMB could be efficient but that doses need to be carefully controlled to avoid toxicity. Expand
Activity, reduced toxicity, and scale-up synthesis of amphotericin B-conjugated polysaccharide.
TLDR
The findings confirm the simplicity and reproducibility of the conjugation allowing this method to be applied on larger scale production, as well as confirming the efficacy of AMB-AG conjugates. Expand
Nanosomal Amphotericin B is an efficacious alternative to Ambisome for fungal therapy.
TLDR
Hemolysis assay indicated that Nanosomal Amphotericin B causes significantly less lysis of red blood cells than Amphoteric in B deoxycholate and was comparable to Ambisome, which is safe, cost effective and provides an alternative option for treatment of fungal disease. Expand
Development of an amphotericin B micellar formulation using cholesterol-conjugated styrene-maleic acid copolymer for enhancement of blood circulation and antifungal selectivity.
TLDR
Results indicate that Cho-SMA/AmB micelles could be an intravenous formulation with high antifungal selectivity, and drug interactants-conjugated SMA system could be applied to a variety of drug-loaded nanomicellar systems. Expand
Antifungal Activity of Amphotericin B Conjugated to Nanosized Magnetite in the Treatment of Paracoccidioidomycosis
TLDR
It is reasonable to believe that amphotericin B coupled to magnetic nanoparticles and stabilized with bilayer lauric acid is a promising nanotool for the treatment of the experimental paracoccidioidomycosis because it exhibited antifungal activity that was similar to that of free amphoteric in B, did not induce adverse effects in therapeutic doses and allowed for a reduction in the number of applications. Expand
Novel biodegradable poly(gamma-glutamic acid)-amphotericin B complexes show promise as improved amphotericin B formulations.
TLDR
In-vivo, AmB/PGGA complexes were significantly more efficacious than both Fungizone® and AmBisome® against experimental murine candidiasis and provide strong evidence that AmB/(gamma-glutamic acid) complexes display better efficacy and safety features than the currently approved AmB products. Expand
Bioanalysis of free and liposomal Amphotericin B in rat plasma using solid phase extraction and protein precipitation followed by LC‐MS/MS
TLDR
The method was successfully applied to pharmacokinetic study of liposomal Amphotericin B in rats and will allow further clinical studies of L‐AMB and provide useful technical support for the assay of otherliposomal drug formulations. Expand
Antifungal efficacy of amphotericin B encapsulated fibrin microsphere for treating Cryptococcus neoformans infection in Swiss albino mice.
TLDR
The current study demonstrating the use of novel amphotericin B loaded fibrin microsphere not only imparts protection to the encapsulated amph esotericin B but also offers an effective strategy to decrease the drug associated toxicities. Expand
Biodistribution and In Vivo Antileishmanial Activity of 1,2-Distigmasterylhemisuccinoyl-sn-Glycero-3-Phosphocholine Liposome-Intercalated Amphotericin B
TLDR
The results suggest that systemic DSHemsPC-AMB-Lip administration may be useful for the treatment of leishmaniasis, and because it costs less to produce DSHEMSPC- AMB- lip than AmBisome, DSHemPC-amB-lip merits further investigation. Expand
Water-soluble amphotericin B-polyvinylpyrrolidone complexes with maintained antifungal activity against Candida spp. and Aspergillus spp. and reduced haemolytic and cytotoxic effects.
TLDR
Water-soluble complexes of AmB and polyvinylpyrrolidone (AmB-PVP) compared favourably with AmB for antifungal activity, were less haemolytic and cytotoxic than AmB, and show a similar cytotoxicity profile to AmBisome. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 51 REFERENCES
Pharmacology and toxicology of a liposomal formulation of amphotericin B (AmBisome) in rodents.
TLDR
Initial pharmacokinetic evaluations demonstrated that peak plasma concentrations of 87 and 118 mg/kg, respectively, were attained in mice and rats after injection with 5mg/kg AmBisome, and tissue accumulations of amphotericin B resulting from multiple dose intravenous administration of either conventional amphoteric in B or AmBISome were determined. Expand
Relationship of pharmacokinetics and drug distribution in tissue to increased safety of amphotericin B colloidal dispersion in dogs
TLDR
Although ABCD increased concentrations of AmB in the reticuloendothelial system, increased toxicity was not observed in these organs, and ABCD was eightfold safer than m-AmB. Expand
Tissue Distribution of Amphotericin B Lipid Complex in Laboratory Animals *
TLDR
ABLC, under development for the treatment of serious fungal disease, is not a true liposome but a complex of amphotericin B, dimyristoyl phosphatidylcholine and dimyristsoylosphatidolglycerol with a particle size range of 1·6–6·0 μm. Expand
Distribution of Lipid Formulations of Amphotericin B into Bone Marrow and Fat Tissue in Rabbits
TLDR
The results of this study show that high concentrations of AmB can be achieved in the bone marrow after administration of lipid formulations, suggesting their particular usefulness against disseminated fungal infections involving theBone marrow and against visceral leishmaniasis. Expand
Carrier effects on biological activity of amphotericin B
TLDR
In vitro investigations have led to the conclusion that the increase in selectivity observed is due to the selective transfer of AmB from lipid complexes to fungal cells or to the higher thermodynamic stability of lipid formulations. Expand
Comparison of the Effects of Liposomal Amphotericin B and Conventional Amphotericin B on Propafenone Metabolism and Hepatic Cytochrome P-450 in Rats
TLDR
It is concluded that Li-AMB, in contrast to AmB, decreases neither hepatic microsomal cytochrome P-450 nor hepatic propafenone metabolism in rats ex vivo, suggesting that it participates in AmB-induced disturbance of hepatic metabolic function. Expand
Acute and chronic effects of flucytosine on amphotericin B nephrotoxicity in rats.
TLDR
It is suggested that FC has a small but significant effect in reducing chronic AmB-induced nephrotoxicity and this amelioration of renal injury is independent of saline administration. Expand
Amphotericin B Lipid Complex or Amphotericin B Multiple-Dose Administration to Rabbits with Elevated Plasma Cholesterol Levels: Pharmacokinetics in Plasma and Blood, Plasma Lipoprotein Levels, Distribution in Tissues, and Renal Toxicities
TLDR
It is suggested that an increase in plasma cholesterol levels modifies the pharmacokinetics of AmB and renal toxicity following the administration of multiple intravenous doses of Doc-AmB and ABLC. Expand
Pharmacokinetics and safety of a unilamellar liposomal formulation of amphotericin B (AmBisome) in rabbits
TLDR
It is concluded that LAmB safely achieved higher Cmax and AUC0-infinity(s) and demonstrated saturable, nonlinear elimination from plasma via reticuloendothelial organ uptake and reduced nephrotoxicity of L AmB correlated with diminished levels of amphotericin B in the kidneys. Expand
Pharmacokinetic profile of ABELCET (amphotericin B lipid complex injection): combined experience from phase I and phase II studies
TLDR
The pharmacokinetics of ABELCET suggest that lower concentrations in blood due to higher clearance and greater distribution may be responsible for its improved toxicity profile compared to those of conventional formulations. Expand
...
1
2
3
4
5
...